1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,850 | 8,050 | 13:02 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| WUXI XDC Aktie jetzt für 0€ handeln | |||||
| Do | WUXI XDC (02268): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON OCTOBER 9, 2025 | - | HKEx | ||
| Do | WUXI XDC Slumps ~5% on Reported Shareholder STA Pharmaceutical's Stake Cut at 6.5% Discount | 1 | AASTOCKS | ||
| 26.09. | WUXI XDC (02268): INTERIM REPORT 2025 | 2 | HKEx | ||
| 23.09. | WUXI XDC (02268): CONTINUING CONNECTED TRANSACTIONS (1) REVISION OF ANNUAL CAPS FOR RELEVANT CCT AGREEMENTS; (2) RENEWAL OF EXISTING CCT AGREEMENTS; AND ... | 3 | HKEx | ||
| 22.09. | HSI Closes at 26,344, Down 200 pts; HSTI Closes at 6,257, Down 36 pts; SUNNY OPTICAL Up over 6%; WUXI BIO, SMIC, FIT HON TENG, COWELL, WUXI XDC Hit New Highs; Market Turnover Rises | 16 | AASTOCKS | ||
| 22.09. | HSI Closes Midday at 26,280, Down 264 pts; HSTI Closes Midday at 6,220, Down 74 pts; MEITUAN Down over 3%; FIT HON TENG, COWELL, WUXI XDC, FIH Hit New Highs | 5 | AASTOCKS | ||
| 22.09. | WUXI XDC (02268): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON THURSDAY, OCTOBER 9, 2025 | 1 | HKEx | ||
| 22.09. | WUXI XDC (02268): NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 22.09. | WUXI XDC (02268): CONNECTED TRANSACTION IN RELATION TO SUBSCRIPTION OF NEW SHARES UNDER SPECIFIC MANDATE AND NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 19.09. | WUXI XDC (02268): CLOSURE OF REGISTER OF MEMBERS | 3 | HKEx | ||
| 10.09. | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 03.09. | BRIEF: WuXi XDC to raise $348 million via share placements at 4% discount | 5 | Bamboo Works | ||
| 03.09. | WUXI XDC (02268): CONNECTED TRANSACTION IN RELATION TO SUBSCRIPTION OF NEW SHARES UNDER SPECIFIC MANDATE | 1 | HKEx | ||
| 03.09. | WUXI XDC (02268): PLACING OF NEW SHARES UNDER GENERAL MANDATE | 2 | HKEx | ||
| 02.09. | WUXI XDC (02268): CONTINUING CONNECTED TRANSACTIONS (1) REVISION OF ANNUAL CAP FOR EXISTING PAYLOAD-LINKERS MASTER SERVICES AGREEMENT AND (2) RENEWAL ... | - | HKEx | ||
| 29.08. | HSBC startet Coverage für WuXi XDC mit "Buy" und sieht 37 % Kurspotenzial | 2 | Investing.com Deutsch | ||
| 29.08. | HSBC initiates WuXi XDC Cayman stock with Buy rating, sees 37% upside | 1 | Investing.com | ||
| 22.08. | WUXI XDC (02268): GRANT OF RESTRICTED SHARES UNDER THE 2024 SHARE SCHEME | 1 | HKEx | ||
| 18.08. | WuXi XDC Continues to Deliver Robust Business Growth and Financial Results in 1H 2025, Strengthening Global CRDMO Leadership Position in Bioconjugates Industry | 102 | PR Newswire | - Revenue increased by 62.2% YoY to RMB 2,701 million - Gross profit surged by 82.2% YoY to RMB 975 million, with its margin of 36.1%- Adjusted net profit before interest income and expense... ► Artikel lesen | |
| 18.08. | WUXI XDC (02268): INSIDE INFORMATION 2025 INTERIM RESULTS PRESENTATION | - | HKEx |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,470 | -1,56 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 20,050 | -3,19 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| EVOTEC | 6,698 | -0,86 % | Evotec Aktie: Strohfeuer oder klappt es diesmal? | Die Evotec Aktie zeigt Stärke - aber diesmal auch für eine längere Zeit? Seit dem 26. September hat sich die TecDAX-notierte Biotech-Aktie von 5,882 Euro um mehr als einen Euro verteuert. Am gestrigen... ► Artikel lesen | |
| 89BIO | 14,800 | -0,34 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| BIONTECH | 87,95 | +0,11 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,305 | -10,24 % | Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference | ||
| BEAM THERAPEUTICS | 26,340 | -5,49 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 10,290 | +9,70 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
| MINERALYS THERAPEUTICS | 42,170 | +7,06 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| ARCELLX | 86,80 | -1,84 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| LENZ THERAPEUTICS | 38,740 | -16,24 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
| APOGEE THERAPEUTICS | 52,45 | -1,43 % | Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million | SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| BICARA THERAPEUTICS | 17,780 | -2,58 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating... ► Artikel lesen | |
| COGENT BIOSCIENCES | 16,250 | +0,37 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,320 | -5,87 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten |
Das Unternehmen WUXI XDC CAYMAN INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -6,51 % bei einem Aktienkurs von 7,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu WUXI XDC CAYMAN INC finden Sie auf Wallstreet Online.